Compounds > [2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium
Page last updated: 2024-08-21

[2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium and Inflammation

[2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium has been researched along with Inflammation in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lee, TL; Niethammer, AG; Timmer, A; Zheng, Z1

Trials

1 trial(s) available for [2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium and Inflammation

ArticleYear
First-in-Human Evaluation of Oral Denatonium Acetate (ARD-101), a Potential Bitter Taste Receptor Agonist: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial in Healthy Adults.
    Clinical pharmacology in drug development, 2022, Volume: 11, Issue:8

    Topics: Acetates; Adult; Animals; Dose-Response Relationship, Drug; Humans; Inflammation; Quaternary Ammonium Compounds; Taste

2022